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Abstract
Background: There have been many efforts to develop efficient vaccines for the control of porcine reproductive
and respiratory syndrome virus (PRRSV). Although inactivated PRRSV vaccines are preferred for their safety, they are
weak at inducing humoral immune responses and controlling field PRRSV infection, especially when heterologous
viruses are involved.
Results: In all groups, the sample to positive (S/P) ratio of IDEXX ELISA and the virus neutralization (VN) titer
remained negative until challenge. While viremia did not reduce in the vaccinated groups, the IDEXX-ELISA-specific
immunoglobulin G increased more rapidly and to significantly greater levels 7 days after the challenge in all the
vaccinated groups compared to the non-vaccinated groups (p < 0.05). VN titer was significantly different in the 10
6
PFU/mL PRRSV vaccine-inoculated and binary ethylenimine (BEI)-inactivated groups 22 days after challenge (p <
0.05). Consequently, the inactivated vaccines tested in this study provided weak memory responses with sequential
challenge without any obvious active immune responses in the vaccinated pigs.
Conclusions: The inactivated vaccine failed to show the humoral immunity, but it showed different immune
response after the challenge compared to mock group. Although the 10
6 PFU/mL-vaccinated and BEI-inactivated
groups showed significantly greater VN titers 22 days after challenge, all the groups were already negative for
viremia.
Background
P o r c i n er e p r o d u c t i v ea n dr e s p i r a t o r ys y n d r o m e( P R R S )
is an economically relevant emerging swine viral disease
that was first recognized in North America in 1987 [1]
and in Europe in 1990 [2]. The causative agent of this
disease, PRRS virus (PRRSV), was first isolated in the
Netherlands in 1990 [2] and was designated Lelystad
virus (LV). Subsequently, the same agent causing PRRS
was also identified in the United States [3]. PRRSV is an
enveloped single-stranded RNA virus of the Arteriviri-
dae family, a member of the order Nidovirales [4].
PRRSV can cause severe reproductive failure in sows
that is characterized by late-term abortion, stillbirth, and
the birth of weak piglets; it is also associated with por-
cine respiratory disease complex in combination with
secondary infections [5,6]. In the US alone, the eco-
nomic losses caused by PRRS amount to more than US
$560 million annually, and it is the most significant
infectious disease currently affecting the swine industry
worldwide [7]. The application of vaccines against
PRRSV began in 1993 in Europe and 1 year later in
North America. Current PRRSV vaccines have 2 forms:
modified live and inactivated virus mixed with adjuvant
[8].
In breeding swine, post-vaccination viremia can be
induced by this live vaccine, and boars can shed live
vaccine virus in their semen [9]. A commercial modified
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many countries, but PRRS outbreaks are quite common
in swine farms despite routine vaccination. These find-
ings justify studying the use of inactivated PRRSV vac-
cines in breeding pigs.
Because the protective immune response induced by
attenuated vaccines is influenced by the genetic diversity
of PRRSV, attenuated vaccines are not always effective
against PRRSV that are genetically different from the
vaccine virus strains [10]. For this reason, many
researchers have tried to develop a killed virus vaccine
that reflects the genetic diversity of PRRSV. Swenson et
al. [9] show that use of a killed vaccine appears to
reduce virus shedding in semen, but the difference in
the number of days of shedding is not statistically signif-
icant compared to that of live vaccine. In contrast, Niel-
s e ne ta l .[ 1 1 ]f o u n dt h a tk i l led vaccine treatment has
no effect on the level and duration of virus shedding in
semen compared to live vaccine. Duran et al. [12]
injected inactivated oily vaccine containing about 10
5.5
median tissue culture infectious doses (TCID50)p e r
dose of a Spanish strain of PRRSV grown in porcine
alveolar macrophages (PAMs) and subsequently chal-
lenged the cells with a live homologous strain. They
showed that vaccinated animals devoid of antibodies, as
determined by an immunoperoxidase monolayer assay
(IPMA) at the time of challenge, were still protected
from experimental PRRSV infection. On the other hand,
despite the fact that Open reading frame 5 (ORF5) cor-
relates well with the neutralizing antibody titer [13], the
recombinant PRRSV ORF5 antigen vaccine did not pro-
duce serum-neutralizing antibodies and failed to show
protection. Joo et al. [14] reported that sows of a
PRRSV-positive herd with detectable serum neutraliza-
tion (SN) antibody levels were not viremic after reexpo-
sure to PRRSV. Osorio et al. [15] showed that increased
SN antibody titer is important, because the SN antibody
response appears to be well correlated with resistance to
infection. The SN antibody against PRRSV protects
against viremia, virus replication in lungs [16], transpla-
cental spreading of the virus, and reproductive failure
[15].
Nilubol et al. [17] compared killed vaccine (KV)-
inoculated infected pigs to infected pigs with and with-
out KV inoculation. In this experiment, the SN titer was
significantly higher in the KV-vaccinated groups after
challenge than in the non-vaccinated groups. However,
virus shedding was not affected. Misinzo et al. [18]
reported a similar result in that the KV does not always
induce neutralizing antibodies, but it enhances neutraliz-
ing antibodies upon viral challenge. Although KV
induced faster antibody production after challenge, it
failed to prevent the clinical signs associated with
PRRSV infection, i.e., post-challenge viremia and trans-
placental infection of the piglets [19].
PRRSV-KVs induce poor immune responses in naïve
pigs [17]. Without neutralizing antibody induction, KVs
can result in a significant
improvement of sow reproductive performance and
litter characteristics [20]. When animals were challenged
with heterologous PRRSV, the vaccine failed to protect
gilts [19]. The efficacy of inactivated PRRSV vaccine has
been seriously questioned [21]. An effective KV program
is thought to produce variable results, according to the
vaccine and vaccination strategy. Misinzo et al. [18]
observed differences in the efficacy of inactivated vac-
cines depending on the virus strain and the cells used to
prepare the vaccines. In addition, some types of adju-
vants can be used as effective vaccine adjuvants to
enhance the humoral and cellular responses of piglets to
PRRSV [22].
Despite frequent vaccine use, there is little existing
information about the protective efficacy or potency of
PRRSV vaccines evaluated through in vivo infectious
challenge with wild-type PRRSV. This study was under-
taken to compare vaccine efficacy according to the virus
antigen quantity and inactivation reagent by analyzing
the virus titer after challenge, ELISA antibody titer, and
VN titer.
Methods
Virus production and plaque assay
PRRSV isolated from Jinwang farm in Chungcheong-
nam-do (virus isolation number: 08-296; Genbank acces-
sion number: HM130677) and propagated in MARC-145
cells was used for experimental vaccine preparation.
After 96 h culture in 2-L roller bottles, the cell culture
supernatants were centrifuged at 6,000 rpm for 20 min.
Virus titers were determined by plaque assay using
MARC-145 cells. For the assay, the cells were pre-
seeded in a 6-well plate at a density of 3 × 10
5 cells/well
for 12-18 h and subsequently infected with serial 10-fold
dilutions of virus for 1 h at 37°C with frequent agitation.
The cell monolayers were then overlaid with minimal
essential medium containing 0.5% SeaKem LE agarose
(FMC BioProducts, Rockland, Maine) and 5% fetal
bovine serum, followed by 4-day incubation at 37°C in
air containing 5% CO2.T h er e s u l t a n tp l a q u e sw e r e
visualized by fixation with 7% formaldehyde followed by
staining with crystal violet (1% [w/v] in 5% ethanol).
Virus inactivation
1. BEI
BEI was prepared as a 0.1 M stock solution by stirring
0.1 M 2-bromoethylamine hydrobromide (Sigma, USA)
in 0.175 M NaOH at 37°C for 1 h, as described pre-
viously [23]. BEI was used shortly after its preparation.
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1% concentration to attain a final BEI concentration of
0.001 M. Virus suspensions were incubated at 37°C for
24 h. The remaining BEI was subsequently neutralized
b yt h ea d d i t i o no f1 0 %o ft h ev o l u m eo fB E Io f1M
sterile sodium thiosulfate (Sigma) solution for 2 h.
2. Formalin
Formaldehyde solution (35%) (Duksan, Korea) was
added to the viral suspensions to attain a final concen-
tration of 0.3%. The formalin-treated viral suspensions
were incubated overnight at 37°C as described pre-
viously {Habib, 2006 #856}.
3. b-propiolactone
The pH of viral suspensions was adjusted to 7.3 using
NaOH. b-propiolactone was then introduced to a final
dilution of 1:2000 (v/v) and mixed on a magnetic stirrer
for 24 h, as described previously [24]. Following inacti-
vation, the viral suspensions were gradually heated to
37°C at pH 7.0 over a period of 24 h.
Preparation of vaccine formulations
To confirm if the viruses were completely inactivated, 1
mL virus suspension was inoculated on MARC-145 cells
in a 175-cm
2 tissue culture flask with 50 mL of Dulbec-
co’s modified Eagle’s medium (DMEM). After the cells
were cultured for 5 days at 37°C, the supernatants were
replaced with fresh culture media and incubated for
another 5 days. Non-inactivated PRRSV was inoculated
on MARC-145 cells as positive control. Cells were ana-
lyzed for cytopathic effects (CPE), and the supernatants
were tested by polymerase chain reaction (PCR) to con-
firm the presence of the virus. After confirmation of
viral inactivation, each viral antigen were mixed with
10% (v/v) aluminum hydroxide adjuvant (Rehydragel,
SEPPIC, France) on a magnetic stirrer (at 180 rpm) for
overnight.
PRRS ELISA
Serum samples were collected from pigs, and aliquots
were prepared and stored at -20°C until ELISA for
PRRSV antibodies was performed. ELISA was performed
using a commercial kit (HerdChek
® PRRS 2XR,
IDEXX), according to the manufacturer’s instructions.
All reagents required for the assay were provided with
the kit, and the assay was conducted at room tempera-
ture. The optical density of each well was measured at
650 nm using the Bio-Rad 680 microplate reader. The
presence or absence of PRRSV antibody was determined
by calculating the sample to positive (S/P) ratio. Samples
were considered to be positive for PRRSV antibody if
the S/P ratio was more than 0.4.
PRRSV VN titer assay
VN titers were determined by SN test on MARC-145
cells. A 2-fold diluted serum sample was prepared, and
an equal volume of virus solution with a titer of 100
TCID50/mL was added to each dilution and incubated
for 1 h at 37°C. The serum-virus mixture was trans-
ferred to a 96-well plate containing a MARC-145 cell
m o n o l a y e r .T h eC P E so nt h ec e l l sw e r ea n a l y z e df o r7
days after inoculation. The VN antibody titer was
defined as the reciprocal of the highest dilution that
inhibited CPE in 50% of the inoculated wells.
Quantitation of PRRSV with real-time PCR
Real-time quantitative PCR was performed using Bio-
Rad iQ5 Real Time PCR Detection System. The 20-μL
PCR mixture comprised 10 μL of the commercially
available mastermix (iQ SYBR Green Supermix; Bio-
Rad), 1 μL of the cDNA extract from the serum of each
pig, 8.5 μL of RNAase-free water, and 0.25 μL of both
forward and reverse primers. In addition, each reaction
included PRRSV standards with progressive dilutions of
1:10, which generated the standard curve for the reac-
tion. The following protocol was used: 5 min at 94°C for
incubation and Taq activation, followed by 40 cycles of
30 s each at 94°C for denaturation, 30 s at 55°C for
annealing, and 45°C for extension. PRRSV content in
each sample was estimated by converting the value for
the cycle threshold (Ct), which was determined with the
Bio-Rad iQ5 qPCR software, to virus titer (copies/mL)
by using the coefficient of correlation from the standard
curve.
Experimental design of animal studies
All animals were serologically tested against PRRSV just
before the experiment to confirm naïve herd status. All
animal experiments complied with the current laws of
South Korea. Animal care and treatment were con-
ducted in accordance with the guidelines established by
the Institutional Animal Care and Use Committee of
Optifarm Solution. Twenty-eight SPF hairless white
Yucatan miniature pigs were used in this experiment.
All pigs were kept in a HEPA-filtered barrier facility.
The pigs had free access to sterilized water and unmedi-
cated sterilized feed.
Twenty-eight SPF miniature pigs were randomly
assigned to 7 treatment groups including a negative
control group. The mock-vaccinated control group
received 2 mL aluminum hydroxide adjuvant. The 10
4,
10
5,a n d1 0
6 groups were vaccinated with 10
4,1 0
5,a n d
10
6 PFU/mL inactivated PRRSV (by the BEI method),
respectively, with 10% (v/v) aluminum hydroxide adju-
vant (Rehydragel, SEPPIC, France). The BEI-, formalin-,
and b-propiolactone-inactivated groups were vaccinated
with PRRSV inactivated by the abovementioned
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6 PFU/
mL, which was mixed with 10% (v/v) aluminum hydro-
xide adjuvant.
All the 7 groups were inoculated with vaccine or
mock-vaccine 3 times 0, 21, and 42 days post inocula-
tion (DPI). At day 70 after initial vaccination, all the ani-
mals (the mock, 10
4,1 0
5,a n d1 0
6 groups) were
challenged intranasally with 10
3.4 TCID50 field-isolated
PRRSV (strain 09-1240 KH, ORF5; Genbank accession
number: GQ375443). Blood was taken on 0, 3, 6, 9, 14,
21, 28, 35, 42, 49, 56, and 70 days after vaccination and
on 0, 3, 4, 7, 10, 15, and 22 days after the challenge.
Serum samples were collected and stored at -70°C
before testing with ELISA, VN, and Q-PCR.
Statistical analysis
ELISA S/P ratio, V/N test results, and viral load were
analyzed by Student’s t-test. A p value less than 0.05
was considered statistically significant.
Results
Measurement of PRRSV-specific antibody levels by IDEXX
ELISA after vaccination according to the viral titer
For the experimental efficacy test according to the viral
titer, PRRSV suspensions of titers of 10
4,1 0
5,o r1 0
6
PFU/mL were inactivated with binary ethylenimine
(BEI) and inoculated into pigs. From 21 to 56 days after
the first vaccination, the 10
6 PFU/mL PRRSV vaccine-
inoculated group showed a significantly higher sample
to positive (S/P) ratio (p < 0.01) than the control group
(Figure 1). However, all groups were serologically nega-
tive as determined by IDEXX ELISA until 70 days of the
first vaccination. The positive and negative cut-offs of
the IDEXX ELISA are at 0.4 S/P ratio. The S/P ratio of
the 10
6 PFU/mL PRRSV vaccine-inoculated group had
the highest S/P ratio at 28 day post-infection (DPI) 28,
14 days after the second injection. This result indicated
that 10
6 PFU/mL killed PRRSV antigen could not
induce enough antibody determined by ELISA.
Variation of PRRSV ELISA S/P ratio after challenge
according to the virus titers
PRRSV-specific antibodies were found to be absent by
ELISA in all the experimental groups before challenge
(Figure 1). Until day 4 after challenge, all the groups
were serologically negative as determined by IDEXX
ELISA (Figure 2). At day 7 after the challenge, all the
vaccinated groups became serologically positive. The
average S/P ratios of the 10
4,1 0
5,a n d1 0
6 PFU/mL
PRRSV-vaccinated groups at 7 days were 0.82, 0.72, and
0.67, respectively. The average S/P ratios of the 10
4 and
10
5 PFU/mL vaccine-inoculated groups were not signifi-
c a n t l yd i f f e r e n tf r o mt h e1 0
6 PFU/mL vaccine-inocu-
lated groups (p > 0.05). However, all vaccine groups
showed significantly different results from the control
group only on the seventh day after challenge (p < 0.01).
This result indicates that, all vaccinated groups showed
faster antibody production than the non-vaccinated
group.
Viral load after challenge with killed vaccine according to
viral titer
The mean post-challenge serum PRRSV level is shown
in Figure 3. The sensitivity threshold of this assay is 10
RNA copies/mL measured by quantitative PCR.
Because day-0 blood was sampled just before inocula-
tion, the virus was not detected. By day 3 after chal-
lenge, all the vaccinated groups showed significantly
different results from the control group (p < 0.05). The
viral load of the control group was lower than those of
the vaccinated groups. On day 4, the viral load of the
10
6 PFU PRRSV-vaccinated group was significantly
higher than that of the control group; no significant dif-
ferences were observed compared to that of the other
groups (p < 0.05). At day 10, the viral loads of the 10
5
and 10
6 PFU/mL PRRSV-vaccinated groups were signifi-
cantly reduced compared with those of the control and
10
4 groups (p < 0.05). There was no difference in viral
load between the control and 10
4,1 0
5,a n d1 0
6 PFU/mL
PRRSV-vaccinated groups. By day 15, viruses were
detected in the control and 10
6 PFU/mL PRRSV-vacci-
nated groups, but there was only a significant difference
between the control and 10
4 PFU/mL PRRSV-vaccinated
groups (p < 0.05).
PRRSV-specific neutralization titer according to BEI-
inactivated viral titers from the samples on day 22 after
challenge
On the last day after challenge, serum samples were
analyzed to determine the difference in the VN titer
obtained with different values of the inoculated viral
titer. Before challenge, all experimental groups were
measured by a VN test and all groups were negative.
Twenty-two days after challenge, the 10
6 viral antigen-
inoculated group exhibited a significantly higher VN
titer compared to the 10
4 and 10
5 PFU/mL virus-inocu-
lated groups (p < 0.01). In this present study, killed vac-
cine failed to induce antibody determined by ELISA. But
BEI-inactivated vaccines showed higher VN titer accord-
ing to viral titer. This result indicated that 10
6 PFU/mL
viral titer of vaccine can induce higher VN titer (Figure
4).
PRRSV-specific ELISA antibody titer with experimental
vaccines according to inactivation methods
In order to test the efficacy of different virus inactiva-
tion methods, PRRSV suspensions were inactivated
using BEI, formalin, or b-propiolactone. Until 70 days
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showed serological negativity (Figure 5), as determined
by the IDEXX ELISA kit. The positive and negative cut-
offs of the IDEXX ELISA were at an S/P ratio of 0.4.
The BEI-inactivated group showed significantly different
S/P ratios compared to the control group from 21 to 56
days after the first vaccine inoculation (p < 0.01). The
highest S/P ratio was observed in the BEI group 14 days
after the second vaccination and 28 days after the pri-
mary vaccination (0.222 (0.1)). In the formalin group,
from 28 to 42 days, only 1 pig (H08-010) had a serologi-
cally positive S/P ratio above 0.4, and its highest value in
that period was 0.68.
Variation in PRRS ELISA S/P ratios after challenge with
vaccines prepared by different virus inactivation methods
The PRRSV-specific antibodies were found to be absent
by ELISA in all the experimental groups before chal-
lenge (Figure 5). Until day 4 after challenge, all the
groups remained serologically negative, as determined
by IDEXX ELISA (Figure 6). At day 7 after challenge,
the average S/P ratio of all vaccinated groups became
serologically positive, except for 1 and 2 pigs in the
formalin-and b-propiolactone-inactivated groups,
respectively.
On the seventh day after challenge, all vaccinated
groups showed significantly different S/P ratios com-
pared to the control group (p <0 . 0 1 ) .T h eS / Pr a t i oo f
the formalin-inactivated group on the tenth day was sig-
nificantly different from that of the control group (p <
0.005). There were no significant differences 15 days
after challenge.
Viral load of the KV-vaccinated group studied according
to the different method of virus inactivation
The mean PRRSV load in the serum samples collected
after the challenge is shown in Figure 7. The threshold
of sensitivity of this assay was 10 RNA copies/mL mea-
sured by quantitative PCR.
The virus was not detected, because the blood samples
were taken just before the challenge. From days 3-4, all
the vaccinated groups, except the b-propiolactone-inac-
tivated group at day 3, had significantly higher viral
loads than the control group (p < 0.05). Ten days after
the challenge, the BEI-inactivated group had a lower
viral load than the control group (p < 0.05). Twenty-two
Figure 1 PRRSV-specific IDEXX ELISA S/P ratio with 3 shots of BEI-inactivated PRRSV experimental inactivated vaccine, according to
viral titers. Vaccines were inoculated 3 times (days 0, 14, and 28).
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vated groups had virus-positive blood.
PRRSV-specific neutralization titer according to virus
inactivation method from the samples collected 22 days
after challenge
On the last day after challenge, the serum samples were
analyzed to determine differences in VN titer, according
to inactivation method used to prepare vaccines (Figure
8). Before challenge, all experimental groups were mea-
sured by VN test, and all groups were negative. Twenty-
two days after the challenge, the BEI-inactivated group
had a significantly higher titer compared to the forma-
lin- and b-propiolactone-inactivated groups (p < 0.01).
Discussion
The total annual economic impact of PRRS on the US
swine producers is estimated at $66.75 million in breed-
ing herds and $493.57 million in growing pig popula-
t i o n s[ 7 ] ;t h es i t u a t i o ni nS o u t hK o r e ai st h es a m e .
Based on a field survey in 2001, 230 of 256 pig farms in
Korea tested positive (89.8%) for PRRSV antibodies [25],
indicating that PRRSV has spread throughout the coun-
try. Thus, for preventive purposes, MLVs costing as
much as 2.5 billion KRW per year are used in South
Korea. Despite the use of live vaccines, the prevalence of
PRRSV has not decreased dramatically. This is because
attenuated vaccines are not always effective against
PRRSVs that are genetically different from the vaccine
virus strain [10]. The PRRSV ORF5 sequence surveil-
lance data since 2007 identified newly emerging PRRSVs
(MN184-like) that have 84.9-87.2% nucleotide similari-
ties compared to VR-2332, based on ORF5 sequence
[26]. Recently, attenuated and inactivated vaccines have
been introduced to control PRRSV in the field. Consid-
ering their safety and flexibility towards emerging virus
strains, KVs are preferred over attenuated vaccines.
However, in spite of these benefits, KVs have failed to
evoke any measurable protective immunity [8] or pro-
tect against clinical signs such as post-challenge viremia
and transplacental infection [19].
The first purpose of this study was to investigate the
effects of experimentally KVs of varying virus titers on
humoral immunity. In this experiment, PFU/mL was
used as the viral particle-measuring method to obtain a
more accurate count. The killed PRRSV vaccine was
inoculated 3 times into SPF miniature pigs at 3-week
intervals. Although all pigs were seronegative according
to the criteria provided by the IDEXX corporation (S/P
ratio < 0.4), the KV group inoculated with 10
6 PFU/mL
Figure 2 PRRSV-specific antibody titer (ELISA S/P ratio) after challenge. The 4 groups were challenged at day 70 post-primary vaccination.
The values shown correspond to the average S/P ratio at each time point.
a Mock group was significantly different from other groups (p < 0.05).
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group (p < 0.05). However, no VN titers were detected
in the entire experimental period before challenge (data
not shown).
Many researchers have tried to establish the effects of
KVs on humoral immunity. Misinzo et al. [19] investi-
gated whether neutralizing antibodies can be induced in
pigs upon vaccination with an inactivated vaccine. The
antibody measuring protocols, which differ from
researcher to researcher, include SN titer [17], IPMA
[18], serum immunoglobulin G [22], and ELISA anti-
body titer [8,19]. In these studies, the effects of KVs on
humoral immunity were undetectable or were detected
at a very low level by using commercial ELISA systems.
There might be a difference between the major anti-
genic epitopes of killed PRRSV vaccines and the ELISA
system. However, Scortti et al. [19] reported that the
first seroconversion resulted with the inoculation of
Suvaxyn (Fort Dodge) KV. By day 21, all vaccinated gilts
had seroconverted with a geometric mean titer (GMT)
of 7.43 (0.44), and a peak of anti-PRRSV antibodies
measured by ELISA was observed on day 70 with a
GMT of 8.22 (0.54) [27]. These varying results allow the
assumption that there are many obstacles to establishing
effective KV combinations and well-matched diagnostic
methods.
In the challenge experiment of the present study, all
vaccinated groups showed faster antibody production
than the control group. Scortti et al. [19] reported that
vaccinated groups produced detectable antibodies 5 days
after challenge and 9 days before the unvaccinated
group. In the present study, PRRSV-specific antibodies
were detected at 7 days, that is, 3 days before the con-
trol group. This may imply that the killed vaccine can
induce enough immune memory for PRRSV, but not
enough to induce active humoral immunity. These find-
ings are very similar to those of Zuckermann et al. [8];
only the challenge time is different (28 days post-pri-
mary vaccination versus 70 days in the present study).
The more rapid development of a post-challenge serolo-
gical response may confer some degree of protective
immunity in pigs [19]. The key point of the present
Figure 3 PRRSV load in serum samples collected after challenge from both vaccinated and control (unvaccinated) groups. Results were
obtained by quantitative PCR and are expressed as copies/mL serum. The 4 groups were challenged at day 70 post-primary vaccination. Bars
represent the average viral load at each time point. Values with superscripts in each experimental day are significantly different (p < 0.05).
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The virus neutralization test titer of the 10
6 viral antigen-inoculated group was significantly greater than those of the 10
4 and 10
5 PFU/mL virus-
inoculated groups (p < 0.05).
Figure 5 PRRSV-specific IDEXX ELISA S/P ratio with 3 shots of experimentally inactivated PRRSV vaccine, according to inactivation
method (BEI, formalin, and b-propiolactone). Vaccines were injected 3 times (day 0, 14, and 28).
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ent viral antigen concentrations ranging from 10
4 PFU/
mL to 10
6 PFU/mL, induced the same pattern of more
rapid humoral response. Only with this data, the 10
4
level of viral antigen inoculation appeared to be suffi-
cient for inducing partial immunity. However, the VN
titer measured 22 days after challenge showed that only
the 10
6 PFU/mL virus-inoculated group had significantly
greater neutralizing antibody titer than the other groups
(p < 0.05). Thus, if this viral neutralization response is
related to protective immunity, it is also expected to
affect the post-challenge serum viral load. In another
study, KV (10
5.5 TCID50)-inoculated animals showed a
shorter period of viremia, indicating that it is possible
that the virus concentration in the blood of vaccinated
animals is lower than that in the non-vaccinated animals
[12].
Misinzo et al. [18] reported that the incomplete pro-
tection of KV vaccines against PRRSV might be caused
by over-inactivation, resulting in the destruction of neu-
tralizing viral epitopes. Virus inactivation procedures
can affect the conservation of inactivated viral epitopes
that are important for the induction of protective immu-
nity [28]. In the present study, the ELISA S/P ratios of
all vaccinated groups were significantly greater than
those of the control group (p < 0.01). Because BEI has
an effect at the genomic level–specifically for nucleic
acids–preserving viral epitopes [28], the BEI-inactivated
group might exhibit a higher S/P ratio than the other
groups. However, BEI had very little adverse effects on
the epitopes, whereas BPL significantly altered and for-
malin partially altered the conformation of most epi-
topes [29]. All the vaccinated groups showed significant
rapid elevation of antibody levels at day 7 (Figure 5),
and the formalin-inactivated group showed significance
at day 10 compared to the control group (p < 0.01).
However, in the VN test, BEI resulted in a significantly
higher VN titer than other inactivation groups. At least
in this experiment, the inactivation method is consid-
ered a key factor affecting the VN titer of inactivated
PRRSV vaccines.
Unexpectedly, in the challenge experiment after vacci-
nation according to the viral titer, the vaccinated groups
showed higher viral loads than the control group until
day 4. This phenomenon was repeated in the challenge
experiment after vaccination according to inactivation
method. Scortti et al. [19] found higher viral loads than
those in a mock-vaccinated group after 3 and 5 days. In
contrast, [30] found lower viral loads in the vaccinated
group than in the mock-vaccinated group. The reason
why vaccinated groups exhibit significantly higher viral
loads in blood is unclear. However, it is clear that while
Figure 6 PRRSV-specific antibody titer (ELISA S/P ratio) after challenge. The 4 groups were challenged 70 days post-primary vaccination.
Values represent the average S/P ratio at each time point.
a Formalin group is significantly different from BEI and mock groups (p < 0.05).
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Page 9 of 12Figure 7 PRRSV load in serum samples after challenge. The results were obtained by quantitative PCR and are expressed as copies/mL of
serum. The 4 groups were challenged on day 70 after primary vaccination. Bars represent the average viral load at each time point. Values with
superscripts in each experimental day are significantly different (p < 0.05).
Figure 8 Virus-specific neutralization titer according to virus inactivation method using the samples 22 days after challenge. The virus
neutralization test titer of the BEI-inactivated group was significantly greater than the formalin- and b-propiolactone-inactivated groups (p <
0.05).
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Page 10 of 12vaccination with inactivated viruses only has a small
effect on viremia levels, it reduces the duration of vire-
mia as reported by other researchers [18].
Conclusions
In conclusion, killed PRRSV vaccines with different con-
centrations of virus titer or based on different inactiva-
tion protocols did not significantly differ in their ability
to induce humoral immunity in pigs even after 3 inocu-
lations. However, all the vaccinated groups reached ser-
opositive status in IDEXX ELISA much before the non-
vaccinated group after challenge, which suggests that
the KV merely potentiates memory response. Although
the 10
6 PFU/mL-vaccinated and BEI-inactivated groups
showed significantly greater VN titers 22 days after chal-
lenge, all the groups were already negative for viremia.
Thus, the BEI-inactivated vaccine with a greater virus
titer should be considered for testing to evaluate the
efficacy of killed PRRSV vaccines.
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